Against all odds: Boy with genetic muscular disorder scores 93.8% in Class X boards
Vihaan Gupta
scored 93.8% in his Class 10
CBSE Board exams
.Though he is enrolled with Lions Public School in Sector 10 of the city, Vihaan can't attend regular classes, his mother Sneha Gupta, a homemaker, told TOI.The 16-year-old was diagnosed with
Duchenne muscular dystrophy
, a rare genetic disorder that weakens muscles over time.
Vihaan used to go to school regularly till Class 5-6. But his condition deteriorated in the years after, and he now uses a wheelchair."We never made him feel as if he was ill. If you keep telling a child you are sick, then mentally, the child's thinking will become negative. He was already good at studies. So, we motivated him a lot. We keep a positive environment at home," Sneha said.
The teenager has opted for humanities with mathematics for classes 11 and 12, and aspires to pursue a career in artificial intelligence and data sciences.Another achiever is Shiva Kaul, an Amity International School student who battled dyslexia and scored 85.2% in CBSE Board exams this year.Shiva's mother Renu Kaul said that he took one-on-one support to manage his studies with the learning disability. Shiva, a commerce student, plans to take up BCom or BBA for higher education.Debanshu Mukherjee, also a Gurgaon resident and Amity student, was diagnosed with dysgraphia, a neurological disorder that affects writing abilities.Debanshu, his family said on Tuesday, took the help of a scribe and secured 91% in Class 12 arts stream. His father is a retired IAF officer and mother, a music teacher, and the teenager is set on following a career in hotel management.'I want to become an IAS officer'As the eldest among four siblings, Kajal has set an example for her sisters.The daughter of an auto-rickshaw driver scored 95% in Class 10 CBSE Board exams and dreams of becoming an IAS officer."I am delighted with the results I've achieved and plan to take up arts stream. I want to become an IAS officer. I am deeply inspired by the respect IAS officers receive in the society and the meaningful impact they have on people's lives," the teenager, who is a student of Amity School, said on Tuesday.Kajal's father Hari Narayan Shah told TOI he wants all of his daughters to do well in their studies and is trying to arrange financial assistance for their future. "I will do all that I can to educate all my daughters and fulfil their dreams… whatever they want to become. I will be the most proud if my daughters study and become independent," he said.
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Hindustan Times
5 hours ago
- Hindustan Times
America's drug regulator is in turmoil
TO APPRECIATE the dilemmas the Food and Drug Administration (FDA) faces when it reviews new drugs targeting rare diseases, consider the recent rollercoaster ride of Sarepta Therapeutics, a biotech firm. In 2023 the FDA granted accelerated approval for its gene therapy for Duchenne muscular dystrophy, a rare genetic disorder that typically causes death in early adulthood. Peter Marks, director of the FDA's biologics centre at the time, approved the treatment despite reviewers' concerns about limited clinical data. Some hailed that as proof the FDA could be nimble in cases where sufferers had few options. The treatment costs an eye-watering $3.2m per patient, so the drug's approval delivered Sarepta a major payday. But in the past four months three patients on Sarepta's treatments have died from acute liver failure. On July 18th the FDA asked the firm to suspend distribution. Within days its stock lost nearly half of its value (see chart 1). Illustration: Vartika Sharma Chart 1 Political drama followed. Laura Loomer, a conspiracy theorist with access to President Donald Trump, accused Vinay Prasad—Dr Marks' successor and a long-standing critic of loosening evidentiary standards for drug approvals—of being a 'leftist saboteur' bent on derailing 'Trump's deregulatory mission'. Her attack was widely seen as criticism of his decision to pause Sarepta's therapy. On July 28th the FDA reauthorised the treatment's use for some younger patients. By the next day Dr Prasad had resigned to 'spend more time with his family'. George Tidmarsh, a physician-scientist newly in charge of the agency's other key drug-evaluation division, became acting head of this one, too. But on August 9th Dr Prasad was re-hired, apparently after being persuaded that the FDA's commissioner, Martin Makary, supported him. Ms Loomer responded by threatening exposés of FDA officials. It is hardly a picture of stable decision-making at an agency responsible for regulating products that account for some 14% of America's GDP. Drugs that target rare diseases, known as orphan drugs, constitute a distinctive segment of the pharmaceutical industry, one that is replete with extraordinary financial promise, scientific risk and knotty ethical considerations. The FDA polices this frontier. It is a treacherous mandate even without interventions by the likes of Ms Loomer. And while the challenges for rare-disease drugs are especially acute, they mirror those facing the entire sector in a regulatory landscape for drugs and new treatments that is growing ever more politicised and unstable. Though 200m-500m people worldwide suffer from rare diseases—and nearly half of these illnesses affect children—drugmakers had long neglected the development of treatments. To spur such work Congress passed the Orphan Drug Act in 1983. It offers companies seven years of market exclusivity. Between the legislation's strong incentives and advances in cell and gene therapies, orphan drugs have become an important sector for biotech firms. Today these therapies account for roughly half of the new drugs the FDA approves. They are lucrative, too. Some companies, such as Sarepta, rely almost entirely on orphan drugs for their revenue. Even Johnson & Johnson, a pharmaceutical giant, earned roughly a third of its revenue from these treatments in 2024, according to Evaluate, a pharmaceutical-analytics firm (see chart 2). Mr Makary, the new commissioner of the FDA, has joined a long line of agency chiefs in calling for faster drug reviews, which can take ten months. In June the FDA launched a pilot scheme to cut that to just a month or two for treatments deemed to support 'national interests'. Because robust randomised trials are often unfeasible for rare diseases given the tiny patient pool, Mr Makary has also talked about developing quicker alternative approval pathways for orphan drugs. But these moves towards innovation have been undermined by the administration's inclination to shoot first and aim later. Speaking on the Megyn Kelly Show, a podcast, Mr Makary announced a plan to speed up drug approvals for ultra-rare diseases by relying on 'a plausible mechanism', meaning a scientific explanation showing that treatments could theoretically lead to improved outcomes. Such a standard would be 'about as low as it goes', argues Daniel Kracov, a lawyer who advises pharmaceutical firms on regulation. However, parents of patients with diseases so rare that they can be impossible to run trials for are pushing for new ways to win approval for novel drugs. Officials at the FDA worry that the push to accelerate approvals without hiring more staff will backfire. One reviewer who works on rare diseases notes that during evaluations of proposed treatments for them, the science can be less familiar, the clinical trials smaller, and approval may hinge on less conventional intermediate evidence. This uncertainty can breed scepticism initially. What often persuades reviewers of a treatment's safety and efficacy is statistical stress-testing and other scrutiny of the evidence that can take months. Speeding this up risks causing reviewers to err on the side of caution, which could lead to fewer approvals, not more. Side effects may include Congress is another source of uncertainty. Lawmakers have so far failed to reauthorise a voucher programme that encouraged drugmakers to pursue treatments for rare pediatric diseases. In exchange, companies received a voucher granting expedited FDA review for another drug. The vouchers are transferable and can be sold for tens of millions of dollars on a secondary market (see chart 3). Amid instability, 'vouchers are selling for more, because there is some possibility that Congress will not get this done by the end of 2026', says David Ridley, a health economist at Duke University. Drug development typically takes a decade or longer, which is why investors prize policy certainty. 'The biggest thing is, you want the FDA to be consistent,' explains Matt Phipps, a biotech analyst at William Blair, an investment bank. 'You want them to tell you something and then stick with it and not change their minds at the last minute.' Smaller biotech firms that fuel early innovation across the industry will struggle most to ride out the volatility. Funding cuts at the National Institutes of Health, the wellspring of biomedical research, and threats of pharmaceutical tariffs have given a hypersensitive industry additional reasons to retreat. More uncertainty at the FDA is likely to make it harder to approve drugs in general, and possibly orphan drugs especially. Rollercoasters are no fun when you have no choice but to ride them. America-s-drug-regulator-is-in-turmoil
India Today
2 days ago
- India Today
Vinay Prasad returns as US vaccine regulator chief days after stepping down
Vinay Prasad is returning to his role overseeing vaccine, gene therapy and blood product regulation at the US Food and Drug Administration a little more than a week after he left the agency."At the FDA's request, Dr Vinay Prasad is resuming leadership of the Center for Biologics Evaluation and Research," US Health and Human Services spokesperson Andrew Nixon said in an emailed statement to left the agency on July 30 after just a few months as director of the center. Endpoints News first reported the return of an oncologist who was a fierce critic of US COVID-19 vaccine and mask mandates, was named the center's director by FDA Commissioner Marty Makary in of Prasad's tenure intensified around the agency's handling of a gene therapy for Duchenne muscular dystrophy from Sarepta Therapeutics FDA-approved therapy played a role in the death of two teens who had advanced DMD. After a third death in a separate experimental gene therapy from the company, the FDA asked Sarepta on July 18 to stop all shipments of the approved DMD therapy, saying it had safety FDA changed course on Sarepta on July 28 and said shipments to the main group of patients for the drug could Loomer, a far-right activist and an ally of US President Donald Trump, posted a blog on July 20 in which she called Prasad a "progressive leftist saboteur" who was undermining the agency's was a physician who joined the agency from the University of California, San Francisco. He has had stints at the National Cancer Institute and the National Institutes of FDA and other health agencies have seen multiple shake-ups in recent months under the leadership of US Health Secretary Robert F Kennedy Jr.- Ends
News18
3 days ago
- News18
CBSE Chairman Rahul Singh Gets Two Year Extension Till November 2027
Last Updated: CBSE Chief Rahul Singh, an IAS officer from the 1996 batch of the Bihar cadre, was appointed to the post on March 13 last year. Senior bureaucrat Rahul Singh has been granted a two-year extension as chairperson of the Central Board of Secondary Education (CBSE), as per an official order. The Appointments Committee of the Cabinet (ACC) has approved the extension of Singh's central deputation tenure for an additional two years beyond November 11, 2025, up to November 11, 2027, according to the order dated August 6 issued by the Personnel Ministry, reported PTI. Singh, an IAS officer from the 1996 batch of the Bihar cadre, was appointed to the post on March 13 last year. Before that, he was serving as the Additional Secretary, Department of Personnel and Training (DoPT). He succeeded Nidhi Chhibber, who was then named Advisor in the Niti Aayog. Meanwhile, CBSE unveiled two initiatives on Thursday, August 7 — the CBSE Career Guidance Dashboard and the CBSE Counseling Hub and Spoke Model. These efforts aim to boost career readiness and psycho-social support for students in the 2025-26 academic session. The Career Guidance Dashboard provides students with tools and resources for informed career exploration, while the Counseling Hub and Spoke School Model aims to enhance mental health support systems through collaboration between CBSE Mentor Hub Schools and Spoke Schools. The initiatives were launched at the CBSE Integrated Office in Sector 23, Dwarka, New Delhi. CBSE Secretary Himanshu Gupta, IAS, had highlighted the importance of structured mental health support and commended schools for their role in guiding students through academic and career challenges. The event featured panel discussions, including a session by CBSE Controller of Examinations Dr Sanyam Bhardwaj on the reforms implemented post-NEP 2020. Representatives from various schools shared their experiences of incorporating career and mental wellness initiatives. The Career Guidance Dashboard, available at is now live. A special session detailed the implementation protocols, responsibilities, and monitoring mechanisms of the CBSE Counseling Hub and Spoke Model. view comments First Published: Disclaimer: Comments reflect users' views, not News18's. Please keep discussions respectful and constructive. Abusive, defamatory, or illegal comments will be removed. News18 may disable any comment at its discretion. By posting, you agree to our Terms of Use and Privacy Policy.
